Valneva is pushing forward with its live-attenuated, single-shot vaccine candidate, VLA1553, for chikungunya, a mosquito-borne viral disease for which there are no preventive vaccines or effective treatments available.
Valneva has been awarded up to £20m ($27m) in R&D funding from Scottish Enterprise: which will be used to revive its plans to increase vaccine manufacturing in Scotland.
The International Vaccine Institute (IVI) and Bharat Biotech have started a Phase 2/3 clinical trial for a chikungunya vaccine candidate in Costa Rica.
Vaccine company Valneva has announced positive Phase 3 pivotal results for its single-shot chikungunya vaccine. “We are a step closer to addressing this major, growing and unmet public health threat,” says the company.
Vaccine company Valneva has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the US Food and Drug Administration (FDA).
